Search

Objective—To measure duration of corneal anesthesia and time and degree of maximal anesthetic effect of 0.5% proparacaine hydrochloride by use of a Cochet-Bonnet aesthesiometer in horses. Animals—10 clinically normal adult horses. Procedures—Baseline corneal touch threshold (CTT) was measured in millimeters for 1 randomly selected eye of each horse by use of the aesthesiometer by applying the filament to the cornea at maximum length (60 mm) and decreasing in 5-mm increments until a consistent blink response was elicited. Following baseline CTT measurement, 0.2 mL of 0.5% proparacaine hydrochloride was instilled in the selected eye. The CTT was measured within 1 minute following proparacaine administration and every 5 minutes thereafter for 60 minutes. A mixed-model ANOVA with tested eye varying between subjects and measurement time varying within subject was used to test for main effects and any interaction between these factors. A contrast between means of baseline and each subsequent CTT identified the duration of corneal anesthesia as the time at which there was no difference from baseline. Maximal anesthetic effect occurred at the time with the lowest mean CTT. Results—Duration of corneal anesthesia achieved by use of proparacaine was 25 minutes, and maximal anesthetic effect occurred within 5 minutes, although CTT never went to 0 in any horse at any time. Conclusions and Clinical Relevance—Duration of corneal anesthesia in horses was shorter than in dogs, and degree of maximal effect was less than in cats and dogs, most likely because of increased sensitivity of the equine cornea, compared with corneal sensitivity in those species.

Objective To evaluate the visual outcome of three techniques of corneal transplantation surgery in treating severe inflammatory keratopathies in the horse. Design Retrospective medical records study. Animals studied Medical records of 206 horses that received corneal transplantation surgery at the University of Florida Veterinary Medical Center from 1993 to 2007 were reviewed. Procedure Data collected from the medical records included signalment, types of ocular lesions, type of transplant surgery performed, length of follow-up, complications, and visual outcomes. Results Full thickness penetrating keratoplasty (PK) was performed in 86 horses for melting ulcers, iris prolapse/descemetoceles, and medically nonresponsive full thickness stromal abscesses (SA). Posterior lamellar keratoplasty (PLK) and deep lamellar endothelial keratoplasty (DLEK) are split thickness penetrating keratoplasties that were utilized for medically nonresponsive deep stromal abscesses (DSA) in 54 and 66 eyes, respectively. The most common postoperative surgical complication was graft rejection and varying degrees of graft opacification. Wound dehiscence and aqueous humor leakage was also a common postoperative problem. A positive visual outcome was achieved for PK, PLK, and DLEK in 77.9%, 98.1%, and 89.4%, respectively. Conclusions Corneal transplantation is a tectonically viable surgery in the horse with an overall success rate of 88.5% in maintaining vision when treating vascularized and infected corneal disease in the horse.

Objective To evaluate the long-term visual outcome of phacoemulsification lens extraction surgery in foals and horses and identify any unique postoperative complications that affect the visual outcome. Procedure This is a retrospective medical records study of phacoemulsification cataract surgery in 95 foals and horses from 1990 to 2013. Results Cataracts were removed by phacoemulsification from 111 eyes of 95 horses ranging in age from 22 days to 26 years (average 8.0 ± 5.7 years). Forty-four of the 95 animals were foals (46.3%). Sixteen horses or foals had surgery bilaterally. One hundred and two eyes were blind preoperatively with 97 eyes (95.1%) having evidence of vision immediately postoperatively. Ninety of the 95 horses (94.7%) regained vision in the immediate postoperative period. Five horses did not recover vision postoperatively. Twenty-four horses had cataracts associated with equine recurrent uveitis (ERU). Trauma was noted as the cause of cataract in 10 horses, and no specific cause for the cataract identified in 61 horses. The combined visual outcome data from horses with all types of cataracts (n = 95) found 83 (87.3%) horses to be visual ≤1 month postoperatively, 47 (49.4%) horses visual for >1–6 months postoperatively, 33 (34.7%) horses visual from >6 to 12 months postoperatively, and 25 horses (26.3%) visual >24 months postoperatively. Conclusion The results of phacoemulsification cataract surgery in horses indicate at least 26.3% of horses are still visual and able to continue their natural activity for 2 years or more postoperatively.

The purpose of this review is to discuss the evolution of equine cataract surgery over the past 50 years to its current stage. Equine cataract surgery is performed similarly compared with the techniques used in human ophthalmology and in other veterinary species. However, enough differences exist to make surgical lens removal and intraocular lens implantation in the horse an intrinsically unique endeavour. Due to the size of the adult equine globe, the introduction of species-specific instrumentation has provided the cornerstone to many of the changes made regarding surgical technique over the last 15-20 years. The continuing development of an equine specific, foldable intraocular lens implant (IOL) has provided much needed data supporting the use of such lenses in the horse to improve upon the post operative visual outcome. Finally, the methods utilised to assess visual capacity and the effects of intraocular lens implantation on the globe (e.g. ocular ultrasonography, electroretinography and streak retinoscopy) are gradually becoming more important in preoperative patient assessment and IOL development in the horse. It is the hope of the authors that a broader group of equine veterinarians will become aware of the many changes that have taken place in equine cataract surgery over the last half-century. Although aspiration was implemented nearly 40 years ago in foals for the treatment of congenital cataracts, phacofragmentation (phacoemulsification) techniques have only recently become routine in mature horses undergoing lens extraction.

Objective—To assess the effect of treatment with a topical ophthalmic preparation of 1.2% nalbuphine solution on corneal sensitivity in clinically normal horses. Animals—8 horses. Procedures—Baseline corneal touch threshold (CTT) was measured (defined as the mean filament length [mm] at which a consistent blink response was elicited) for both eyes of each horse by use of a Cochet-Bonnet aesthesiometer. Subsequently, 0.2 mL of 1.2% nalbuphine solution was instilled in 1 randomly selected eye of each horse, and 0.2 mL of artificial tears solution was instilled in the contralateral eye (control treatment). For all 8 horses, CTT of each eye was measured within 1 minute following nalbuphine or artificial tears administration and every 15 minutes thereafter for 60 minutes. For 5 of the 8 horses, CTT was also measured in both eyes at 120 minutes. Changes in CTT values from baseline over time were assessed, as were differences between treated and control eyes. Results—At any time point, corneal sensitivity following nalbuphine treatment did not differ significantly from control treatment findings. Mean CTTs for nalbuphine-treated and control eyes were 38.8 and 37.9 mm, respectively. In both groups, CTT was significantly lower than baseline value at 15, 45, 60, and 120 minutes. No tearing or redness developed in any eye treated with nalbuphine. Conclusions and Clinical Relevance—Topical administration of ophthalmic 1% nalbuphine solution had no effect on corneal sensitivity in clinically normal horses. The topical ocular treatment was not associated with local irritation.

Amniotic membrane transplantation (AMT) is an effective clinical therapy for reconstruction of the ocular surface in human and veterinary patients. Amnion is avascular and strong, contains antiangiogenic and antiinflammatory properties and growth factors, and has properties that prevent or decrease fibrosis in healing tissue. Indications for its use are steadily growing and include grafting to replace diseased, missing or excised tissue, patching to support diseased tissue during the healing process and as a substrate for the expansion of epithelial cells for transplantation to the cornea. AMT through a combination of mechanical and biologic factors can preserve the integrity of the globe, optimize the visual outcome, and minimize scarring in severely diseased corneas.